TONINI, GIUSEPPE
 Distribuzione geografica
Continente #
AS - Asia 21.250
NA - Nord America 5.345
EU - Europa 2.000
SA - Sud America 1.317
AF - Africa 145
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 2
Totale 30.124
Nazione #
SG - Singapore 15.337
US - Stati Uniti d'America 5.089
CN - Cina 2.500
HK - Hong Kong 2.256
BR - Brasile 991
GB - Regno Unito 633
VN - Vietnam 624
IT - Italia 434
DE - Germania 277
IN - India 151
AR - Argentina 143
CA - Canada 136
NL - Olanda 105
FI - Finlandia 82
MX - Messico 82
ID - Indonesia 78
ZA - Sudafrica 73
EC - Ecuador 55
AU - Australia 54
JP - Giappone 52
UA - Ucraina 52
ES - Italia 51
TR - Turchia 50
PL - Polonia 47
FR - Francia 45
BD - Bangladesh 40
CZ - Repubblica Ceca 36
RU - Federazione Russa 33
CO - Colombia 31
SE - Svezia 28
PY - Paraguay 27
EE - Estonia 24
PE - Perù 24
CH - Svizzera 21
CL - Cile 19
LT - Lituania 18
BG - Bulgaria 16
BE - Belgio 15
VE - Venezuela 15
AT - Austria 14
IQ - Iraq 14
KR - Corea 13
TW - Taiwan 12
UZ - Uzbekistan 12
EG - Egitto 11
MA - Marocco 11
IL - Israele 10
RO - Romania 9
SA - Arabia Saudita 9
TH - Thailandia 8
TN - Tunisia 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
JO - Giordania 7
PH - Filippine 7
SI - Slovenia 7
AZ - Azerbaigian 6
BA - Bosnia-Erzegovina 6
DZ - Algeria 6
HU - Ungheria 6
PK - Pakistan 6
BY - Bielorussia 5
IE - Irlanda 5
IR - Iran 5
KW - Kuwait 5
KZ - Kazakistan 5
MY - Malesia 5
OM - Oman 5
PT - Portogallo 5
AL - Albania 4
BH - Bahrain 4
DM - Dominica 4
GT - Guatemala 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
CI - Costa d'Avorio 3
CY - Cipro 3
ET - Etiopia 3
KE - Kenya 3
KH - Cambogia 3
LB - Libano 3
ML - Mali 3
NI - Nicaragua 3
NO - Norvegia 3
PA - Panama 3
TT - Trinidad e Tobago 3
UG - Uganda 3
XK - ???statistics.table.value.countryCode.XK??? 3
AQ - Antartide 2
BB - Barbados 2
BF - Burkina Faso 2
BO - Bolivia 2
CR - Costa Rica 2
CU - Cuba 2
FK - Isole Falkland (Malvinas) 2
GA - Gabon 2
GR - Grecia 2
HN - Honduras 2
Totale 30.070
Città #
Hong Kong 2.241
Singapore 1.772
Ashburn 1.391
Hefei 1.202
Boardman 703
London 555
Dallas 457
San Jose 449
Beijing 409
Shanghai 406
Ho Chi Minh City 240
Los Angeles 154
Council Bluffs 147
San Francisco 138
Munich 134
Hanoi 119
São Paulo 114
Rome 87
Pune 85
Seattle 84
Toronto 78
Santa Clara 69
New York 66
Amsterdam 63
Washington 62
Turku 50
Rio de Janeiro 45
Warsaw 44
Johannesburg 43
Mexico City 43
Tokyo 41
Brno 34
Brooklyn 33
Montreal 32
Helsinki 31
Melbourne 31
Chicago 30
Milan 28
Da Nang 27
Chennai 25
Stockholm 23
Thái Bình 23
Boston 22
Naples 22
Buenos Aires 21
Guayaquil 21
Biên Hòa 19
Atlanta 18
Belo Horizonte 18
Haiphong 18
Phoenix 16
Secaucus 16
Asunción 15
Brasília 15
Quito 15
Boydton 14
Denver 14
Lima 14
Porto Alegre 14
West Jordan 14
Ankara 13
Burgas 13
Hanover 13
Canberra 12
Charlotte 12
Curitiba 12
Hasselt 12
Manchester 12
Poplar 12
Ribeirão Preto 12
St Louis 12
Tashkent 12
Fortaleza 11
Hải Dương 11
Jakarta 11
Manaus 11
Ninh Bình 11
Sydney 11
Thái Nguyên 11
Can Tho 10
Guangzhou 10
Padova 10
Phủ Lý 10
Salvador 10
Sona 10
Lấp Vò 9
Maceió 9
Osasco 9
The Dalles 9
Campinas 8
Caxias do Sul 8
Central 8
Frankfurt am Main 8
Haikou 8
Jinan 8
Las Vegas 8
Redmond 8
Xi'an 8
Amman 7
Baghdad 7
Totale 12.520
Nome #
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC 263
A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: An open-label, non randomized, pilot study 239
A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss 235
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases 224
A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile. 224
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment 218
ANGIOGENESIS AND ONCOGENES IN COLON CANCER 218
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence 215
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer 213
Early impairment of food intake in patients newly diagnosed with cancer 211
COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables 211
Chondrosarcoma of the iliac wing in Von Hippel-Lindau disease 210
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung) 210
96P Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens 207
Complementary use of local excision and transanal endoscopic microsurgery for rectal cancer after neoadjuvant chemoradiation 207
A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation 206
S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury 205
Artificial Intelligence in Detection, Management, and Prognosis of Bone Metastasis: A Systematic Review 203
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions 201
Premetastatic niche: ready for new therapeutic interventions? 200
Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients 200
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features 199
COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification 199
In Situ Identification of CD44+/CD24− cancer cells in primary human breast carcinomas 198
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 198
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial 195
Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study 195
Enoxiparin effects depend on body-weight and current doses my be inadequate in obese patients 194
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients 191
Bisphosphonates: new antiangiogenic molecules in cancer treatment? 191
Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma 191
Prevention of radiotherapy-induced emesis 191
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials 190
COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters 190
[Methodological issues and first results of a record linkage between AIDS and Cancer Registries in Italy 189
Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient 186
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients 184
Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity 183
Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities 182
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 180
A staphylococcus aureus coinfection on a COVID-19 pneumonia in a breast cancer patient 178
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 177
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging 175
Docetaxel induced pericardial effusion 174
Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients 162
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients 151
BOMB trial: First results of stereotactic radiotherapy to primary breast tumor in metastatic breast cancer patients 134
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 133
A giant sarcoma of the parotid gland: A case report and review of the literature 127
Concurrent Use of Abemaciclib and Radiotherapy in Metastatic Breast Cancer Patients: A Single-Center Experience 125
'Internal bracing' surgery in the management of solid tumor metastases of the thoracic and lumbar spine 121
'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer 121
Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect 119
Prospective observational multicentric case-control study about 'fatigue' in patients with history of breast cancer 116
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome 114
A pathology-based combined model to identify pam50 non-luminal intrinsic disease in hormone receptor-positive HER2-negative breast cancer 114
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid 113
A close relationship between HIF-1α expression and bone metastases in advanced NSCLC, a retrospective analysis 112
'Old' and 'new' drugs for the treatment of cancer pain 112
Colorectal carcinomas and PTEN/MMAC1 gene mutations 111
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity 110
Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature 109
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 106
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review 105
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 104
Biological effects of cabozantinib on bone microenvironment 104
Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series 104
A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study 104
An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer 103
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer 103
Carcinoma of the Ampulla of Vater morphological and immunophenotypical classification predicts overall survival 103
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours 103
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 102
[Neoplastic hypercalcemia]. 102
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial 102
Abstract P5-04-13: Antibody-based therapy targeting integrin a5 is an effective strategy to treat experimental breast cancer bone metastasis 102
A form to report pain assessment and monitoring in the oncology clinical record: a Delphi process 100
Cerebellar metastasis from pancreatic adenocarcinoma. A case report 100
Azygo-tracheal fistula in a complete implantable central venous system 100
Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma 100
Body Mass Index and Impaired Fasting Blood Glucose as Predictive Factors of Efficacy in Cetuximab-Based Colorectal Cancer Treatment 100
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients 99
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 99
[Aztreonam and oxacillin in the treatment of febrile neutropenic patients with solid tumors]. 99
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin 99
Biological effects of cabozantinib on osteosarcoma-bone microenvironment model 99
Idiosyncratic reaction after oxaliplatin infusion 98
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw 98
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients 98
Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report 98
How I Treat Localized Soft Tissue Sarcomas: Update on Diagnosis, Risk Stratification, and Treatment 97
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 97
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions 97
Atypical chronic head and neck pain: don't forget Eagle's syndrome 96
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 96
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. 95
Antitumor effect of cabozantinib in bone metastatic models of renal cell carcinoma 95
An omental mass: any hypothesis? 94
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs). 93
Cox-2 Expression in Different Histotypes of Ampullary Carcinoma 93
Totale 14.841
Categoria #
all - tutte 267.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 267.008


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022839 0 5 8 11 63 5 6 5 20 22 19 675
2022/2023202 22 7 3 19 9 8 18 18 12 1 76 9
2023/20242.026 46 228 137 146 186 872 21 131 26 67 78 88
2024/202519.040 311 224 781 138 150 472 324 79 1.660 1.529 6.204 7.168
2025/20268.171 1.669 739 1.263 2.160 674 1.141 525 0 0 0 0 0
Totale 30.278